Creative Planning
VRCA icon

Creative Planning’s Verrica Pharmaceuticals VRCA Stock Holding History

Creative Planning’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,908
Closed -$10.1K – 4026
2025
Q2 		$10.1K Buy
1,908
+6
+0.3% +$32 ﹤0.01% 3623
2025
Q1 		$8.41K Hold
1,902
– – ﹤0.01% 3430
2024
Q4 		$13.3K Hold
1,902
– – ﹤0.01% 3368
2024
Q3 		$27.6K Sell
1,902
-1,090
-36% -$49.1K ﹤0.01% 3135
2024
Q2 		$218K Buy
2,992
+1,090
+57% +$83.7K ﹤0.01% 2615
2024
Q1 		$113K Hold
1,902
– – ﹤0.01% 2685
2023
Q4 		$139K Hold
1,902
– – ﹤0.01% 2518
2023
Q3 		$73.9K Hold
1,902
– – ﹤0.01% 2436
2023
Q2 		$110K Hold
1,902
– – ﹤0.01% 2330
2023
Q1 		$124K Sell
1,902
-100
-5% -$6.05K ﹤0.01% 2218
2022
Q4 		$55K Buy
2,002
+524
+35% +$14K ﹤0.01% 2213
2022
Q3 		$43K Buy
+1,478
New +$50.6K ﹤0.01% 2127
2021
Q1 		– Sell
-2,000
Closed -$230K – 2735
2020
Q4 		$230K Hold
2,000
– – ﹤0.01% 1790
2020
Q3 		$155K Hold
2,000
– – ﹤0.01% 1749
2020
Q2 		$220K Buy
+2,000
New +$231K ﹤0.01% 1477

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Creative Planning's VRCA Position: Q3 2025 in Review

Creative Planning sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 1,908 shares — an estimated $10.1K sold.

Creative Planning first reported a position in VRCA in Q2 2020 and held it in 15 quarters. The position peaked at $230K in Q4 2020. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

  • Creative Planning reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Creative Planning sold 1,908 Verrica Pharmaceuticals shares in Q3 2025, an estimated $10.1K.
  • Creative Planning first reported a position in Verrica Pharmaceuticals in Q2 2020 and held it in 15 quarters.
  • Creative Planning's Verrica Pharmaceuticals position peaked at $230K in Q4 2020.
  • 34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Creative Planning's 13F filing for Q3 2025, filed 14 Nov 2025.